OPU
TLSI icon

Omni Partners US’s TriSalus Life Sciences TLSI Stock Holding History

Omni Partners US’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$4.63M Buy
466,196
+245,225
+111% +$2.4M 0.24% 83
2021
Q2 		$2.14M Buy
+220,971
New +$2.17M 0.09% 108

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Omni Partners US's TLSI Position: Q3 2021 in Review

Omni Partners US increased its TriSalus Life Sciences (TLSI) stake by 111% in Q3 2021, buying an estimated $2.4M and bringing the position to 466,196 shares worth $4.63M. The position accounts for 0.24% of the portfolio, ranked #83.

Omni Partners US first reported a position in TLSI in Q2 2021 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold TLSI as of Q3 2021.

  • Omni Partners US held 466,196 shares of TriSalus Life Sciences worth $4.63M as of Q3 2021.
  • Omni Partners US bought 245,225 TriSalus Life Sciences shares in Q3 2021, an estimated $2.4M.
  • TriSalus Life Sciences made up 0.24% of Omni Partners US's portfolio in Q3 2021, its #83 holding.
  • Omni Partners US first reported a position in TriSalus Life Sciences in Q2 2021 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.